Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NDF-RT |
N0000175669
Created by
admin on Mon Mar 31 18:22:55 GMT 2025 , Edited by admin on Mon Mar 31 18:22:55 GMT 2025
|
||
|
NCI_THESAURUS |
C274
Created by
admin on Mon Mar 31 18:22:55 GMT 2025 , Edited by admin on Mon Mar 31 18:22:55 GMT 2025
|
||
|
WHO-VATC |
QL01XX24
Created by
admin on Mon Mar 31 18:22:55 GMT 2025 , Edited by admin on Mon Mar 31 18:22:55 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
ONCASPAR (AUTHORIZED: PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA)
Created by
admin on Mon Mar 31 18:22:55 GMT 2025 , Edited by admin on Mon Mar 31 18:22:55 GMT 2025
|
||
|
WHO-ATC |
L01XX24
Created by
admin on Mon Mar 31 18:22:55 GMT 2025 , Edited by admin on Mon Mar 31 18:22:55 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/08/569
Created by
admin on Mon Mar 31 18:22:55 GMT 2025 , Edited by admin on Mon Mar 31 18:22:55 GMT 2025
|
||
|
LIVERTOX |
744
Created by
admin on Mon Mar 31 18:22:55 GMT 2025 , Edited by admin on Mon Mar 31 18:22:55 GMT 2025
|
||
|
NDF-RT |
N0000006477
Created by
admin on Mon Mar 31 18:22:55 GMT 2025 , Edited by admin on Mon Mar 31 18:22:55 GMT 2025
|
||
|
NCI_THESAURUS |
C29726
Created by
admin on Mon Mar 31 18:22:55 GMT 2025 , Edited by admin on Mon Mar 31 18:22:55 GMT 2025
|
||
|
FDA ORPHAN DRUG |
39589
Created by
admin on Mon Mar 31 18:22:55 GMT 2025 , Edited by admin on Mon Mar 31 18:22:55 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
7D96IR0PPM
Created by
admin on Mon Mar 31 18:22:55 GMT 2025 , Edited by admin on Mon Mar 31 18:22:55 GMT 2025
|
PRIMARY | |||
|
C042705
Created by
admin on Mon Mar 31 18:22:55 GMT 2025 , Edited by admin on Mon Mar 31 18:22:55 GMT 2025
|
PRIMARY | |||
|
5082
Created by
admin on Mon Mar 31 18:22:55 GMT 2025 , Edited by admin on Mon Mar 31 18:22:55 GMT 2025
|
PRIMARY | |||
|
130167-69-0
Created by
admin on Mon Mar 31 18:22:55 GMT 2025 , Edited by admin on Mon Mar 31 18:22:55 GMT 2025
|
PRIMARY | |||
|
BB-14
Created by
admin on Mon Mar 31 18:22:55 GMT 2025 , Edited by admin on Mon Mar 31 18:22:55 GMT 2025
|
PRIMARY | |||
|
C1200
Created by
admin on Mon Mar 31 18:22:55 GMT 2025 , Edited by admin on Mon Mar 31 18:22:55 GMT 2025
|
PRIMARY | |||
|
m2096
Created by
admin on Mon Mar 31 18:22:55 GMT 2025 , Edited by admin on Mon Mar 31 18:22:55 GMT 2025
|
PRIMARY | Merck Index | ||
|
DB00059
Created by
admin on Mon Mar 31 18:22:55 GMT 2025 , Edited by admin on Mon Mar 31 18:22:55 GMT 2025
|
PRIMARY | |||
|
SUB03666MIG
Created by
admin on Mon Mar 31 18:22:55 GMT 2025 , Edited by admin on Mon Mar 31 18:22:55 GMT 2025
|
PRIMARY | |||
|
PEGASPARGASE
Created by
admin on Mon Mar 31 18:22:55 GMT 2025 , Edited by admin on Mon Mar 31 18:22:55 GMT 2025
|
PRIMARY | |||
|
34132
Created by
admin on Mon Mar 31 18:22:55 GMT 2025 , Edited by admin on Mon Mar 31 18:22:55 GMT 2025
|
PRIMARY | RxNorm | ||
|
Pegaspargase
Created by
admin on Mon Mar 31 18:22:55 GMT 2025 , Edited by admin on Mon Mar 31 18:22:55 GMT 2025
|
PRIMARY | |||
|
100000085540
Created by
admin on Mon Mar 31 18:22:55 GMT 2025 , Edited by admin on Mon Mar 31 18:22:55 GMT 2025
|
PRIMARY | |||
|
CHEMBL2108546
Created by
admin on Mon Mar 31 18:22:55 GMT 2025 , Edited by admin on Mon Mar 31 18:22:55 GMT 2025
|
PRIMARY | |||
|
7D96IR0PPM
Created by
admin on Mon Mar 31 18:22:55 GMT 2025 , Edited by admin on Mon Mar 31 18:22:55 GMT 2025
|
PRIMARY | |||
|
6665
Created by
admin on Mon Mar 31 18:22:55 GMT 2025 , Edited by admin on Mon Mar 31 18:22:55 GMT 2025
|
PRIMARY |
ACTIVE MOIETY